Alnylam Pharmace. buy BMO Capital Markets
Start price
24.06.25
/
50%
€279.80
Target price
24.06.26
€310.57
Performance (%)
-0.14%
Price
22:26
€279.40
Summary
This prediction is currently active. The BUY prediction by BMO_Capital_Markets for Alnylam Pharmace. is nearly unchanged. This prediction currently runs until 24.06.26. The prediction end date can be changed by BMO_Capital_Markets at any time. BMO_Capital_Markets has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | -2.395% |
| iShares Core DAX® | -0.081% |
| iShares Nasdaq 100 | -0.201% |
| iShares Nikkei 225® | 1.465% |
| iShares S&P 500 | 0.215% |
Comments by BMO_Capital_Markets for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at BMO Capital Markets from $300.00 to $360.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by BMO_Capital_Markets for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€210.70
24.06.24
24.06.24
€218.11
24.06.25
24.06.25
32.04%
25.06.25
25.06.25
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€141.40
27.03.24
27.03.24
€216.31
27.03.25
27.03.25
74.96%
28.03.25
28.03.25